Literature DB >> 15925980

Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment?

Hans Theodor Eich1, Rolf-Peter Müller, Oliver Micke, Martin Kocher, Frank Berthold, Barbara Hero.   

Abstract

BACKGROUND AND
PURPOSE: Only 3% of all malignant intranasal tumors are esthesioneuroblastomas (ENB) and only 20% of these rare neuroectodermal tumors are diagnosed up to 20 years of age. Radiotherapy and surgery are established treatment modalities for these patients, but the role of chemotherapy, especially in a multimodal approach, is not well defined. To investigate the influence of radio- and chemotherapy, the treatment and course of the disease in children and adolescents with ENB were analyzed retrospectively. PATIENTS AND METHODS: 19 unselected patients (nine male and ten female) diagnosed with ENB < or = 20 years of age were included in this analysis. Median age at diagnosis was 14.0 years (range, 5-20 years). The tumors were Kadish stage B in 4/19 patients and stage C in 15/19 patients. 17 patients underwent surgery, either without further therapy (n = 4), followed by radiotherapy (n = 1) or as part of multimodal regimens (n = 12). Two patients received radio- and chemotherapy without surgery. Complete resection (R0) was achieved in 15 out of 17 patients with surgery including all five patients with preoperative chemotherapy due to unresectable primary at diagnosis.
RESULTS: The 5-year overall survival (OS) for the whole group was 73% +/- 12% and the 5-year event-free survival (EFS) 55% +/- 13%. None of the four patients with stage B experienced tumor progression so far, whereas seven out of 15 patients with stage C did (5-year EFS 47% +/- 14%; not significant). Patients with Kadish stage C and multimodal treatment strategies combing surgery, chemo- and radiotherapy had a significantly better outcome than patients with stage C and less than three treatment modalities (65% +/- 17% vs. 20% +/- 18%; p = 0.02).
CONCLUSION: These data indicate a benefit of multimodal treatment regimens combining surgery, chemo- and radiotherapy for pediatric patients with ENB Kadish stage C. Chemotherapy appears to improve resectability, EFS, and OS. Radiotherapy is an integral part in the management of children and young adolescents with ENB in Kadish stage B and C.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15925980     DOI: 10.1007/s00066-005-1362-2

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  11 in total

1.  Salvage Treatment of Local Recurrence in Esthesioneuroblastoma: A Meta-analysis.

Authors:  Mitchell R Gore; Adam M Zanation
Journal:  Skull Base       Date:  2011-01

2.  Esthesioneuroblastoma in pediatric and adolescent age. A report from the TREP project in cooperation with the Italian Neuroblastoma and Soft Tissue Sarcoma Committees.

Authors:  Gianni Bisogno; Pietro Soloni; Massimo Conte; Marta Podda; Andrea Ferrari; Alberto Garaventa; Roberto Luksch; Giovanni Cecchetto
Journal:  BMC Cancer       Date:  2012-03-25       Impact factor: 4.430

3.  Multimodality Treatment of Pediatric Esthesioneuroblastoma.

Authors:  Rajkumar Venkatramani; Hubert Pan; Wayne L Furman; Jonathan M Marron; Josephine Haduong; Paola Friedrich-Medina; Anita Mahajan; Abhishek Bavle; Hao Wu; Murali Chintagumpala
Journal:  Pediatr Blood Cancer       Date:  2015-10-30       Impact factor: 3.167

4.  Association of telomerase activity with radio- and chemosensitivity of neuroblastomas.

Authors:  Simone Wesbuer; Claudia Lanvers-Kaminsky; Ines Duran-Seuberth; Tobias Bölling; Karl-Ludwig Schäfer; Yvonne Braun; Normann Willich; Burkhard Greve
Journal:  Radiat Oncol       Date:  2010-07-19       Impact factor: 3.481

5.  Proton therapy for pediatric and adolescent esthesioneuroblastoma.

Authors:  John T Lucas; Matthew M Ladra; Shannon M MacDonald; Paul M Busse; Alison M Friedmann; David H Ebb; Karen J Marcus; Nancy J Tarbell; Torunn I Yock
Journal:  Pediatr Blood Cancer       Date:  2015-03-27       Impact factor: 3.838

6.  Complex Skull Base Reconstructions in Kadish D Esthesioneuroblastoma: Case Report.

Authors:  Sheri K Palejwala; Saurabh Sharma; Christopher H Le; Eugene Chang; Audrey B Erman; G Michael Lemole
Journal:  J Neurol Surg Rep       Date:  2017-04

7.  Model to predict cause-specific mortality in patients with olfactory neuroblastoma: a competing risk analysis.

Authors:  Lipin Liu; Qiuzi Zhong; Ting Zhao; Dazhi Chen; Yonggang Xu; Gaofeng Li
Journal:  Radiat Oncol       Date:  2021-06-10       Impact factor: 3.481

8.  Delaying Postoperative Radiotherapy in Low-Grade Esthesioneuroblastoma: Is It Worth the Wait?

Authors:  Satoshi Kiyofuji; Vijay Agarwal; Joshua D Hughes; Robert L Foote; Jeffrey R Janus; Eric J Moore; Caterina Giannini; Michael J Link; Jamie J Van Gompel
Journal:  J Neurol Surg B Skull Base       Date:  2020-03-25

9.  Intensity Modulated Radiotherapy (IMRT) and Fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma.

Authors:  Stephanie E Combs; Wolfgang Behnisch; Andreas E Kulozik; Peter E Huber; Jürgen Debus; Daniela Schulz-Ertner
Journal:  BMC Cancer       Date:  2007-09-13       Impact factor: 4.430

10.  Complications of Advanced Kadish Stage Esthesioneuroblastoma: Single Institution Experience and Literature Review.

Authors:  Sheri K Palejwala; Saurabh Sharma; Christopher H Le; Eugene Chang; Michael Lemole
Journal:  Cureus       Date:  2017-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.